Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer-Reference-Cited by-同舟云学术

Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer

Published:2015-07 Issue:1 Volume:138 Page:18-23
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

McMeekin Scott,Dizon Don^ORCID,Barter James,Scambia Giovanni,Manzyuk Lyudmila^ORCID,Lisyanskaya Alla,Oaknin Ana^ORCID,Ringuette Sarah,Mukhopadhyay Pralay^ORCID,Rosenberg Julie,Vergote Ignace

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference20 articles.

1. Cancer Facts & Figs. 2015;American Cancer Society,2015

2. Endometrial cancer;Amant;Lancet,2005

3. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Plataniotis;Ann. Oncol.,2010

4. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies;Hogberg;Eur. J. Cancer,2010

5. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group;Aapro;Ann. Oncol.,2003

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial;BMC Medicine;2024-08-26

2. Pan-cancer proteogenomics expands the landscape of therapeutic targets;Cell;2024-08

3. Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/ mismatch repair-deficient solid tumors;CHINESE J CANCER RES;2024

4. A comprehensive analysis of immunotherapy in advanced endometrial cancer (Review);Oncology Letters;2023-12-28

5. Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study;Cell Reports Medicine;2023-12